We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Transfusions Improved for Preterm Infants

By LabMedica International staff writers
Posted on 06 Dec 2012
Transfusion of packed red blood cells (PRBCs) saves lives in the neonatal critical care setting and is one of the most common interventions in the preterm infant.

The number and volume of PRBC transfusions are associated with several major neonatal morbidities, although a direct causal link between transfusion and major neonatal morbidity has yet to be proven. More...


Scientists at the Robinson Institute, the University of Adelaide, (Australia) studied 28 preterm babies at 28 weeks' gestation or less, who were given packed red blood cell transfusions. Plasma inflammatory cytokines and markers of endothelial activation were measured in the infants before and two to four hours after transfusion, as well as in the donor pack. The median age range at transfusion was 18 days with the pretransfusion hemoglobin level at 9.8 g/dL, with a range of 7.4–10.2 g/dL.

The interleukin (IL)-1β, IL-8, tumor necrosis factor-α, and the monocyte chemoattractant protein were increased after transfusion. A similar elevation in markers of endothelial activation was seen after transfusion with increased plasma macrophage inhibitory factor and soluble intracellular adhesion molecule. Cytokines were analyzed by Milliplex MAP Human Cytokine/Chemokine enzyme-linked immunosorbent assays (ELISA) (Merck Millipore; Billerica, MA, USA).

Michael J. Stark, PhD, the lead author of the study said, "Within two to four hours of preterm babies receiving a blood transfusion, we have seen elevated levels of cytokines and chemokines, signaling cells that stimulate inflammatory responses in the body. We believe that the bioactive components of packed red blood cell transfusions are initiating or amplifying these inflammatory processes in the body. "The authors concluded that production of inflammatory cytokines and immunoactivation of the endothelium observed after the transfusion of PRBCs in the preterm infant may be a manifestation of transfusion-related immunomodulation (TRIM). The study was published on November 21, 2012, in the journal Pediatric Research.

Related Links:

University of Adelaide
Merck Millipore




New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Multi-Chamber Washer-Disinfector
WD 390
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.